Frost & Sullivan: iRegene Therapeutics Honored as "2025 Forbes China Leading Enterprises in Industry Development"
Shanghai, China--(Newsfile Corp. - June 8, 2025) - Recently, The "2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor," jointly organized by Frost & Sullivan and Forbes China, was successfully held at Regent Shanghai on The Bund.
Amid the global trend of industrial innovation, the results of the "2025 Pioneer Innovators in Industry Development" selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. iRegene Therapeutics was honored as one of Forbes China's 2025 Leading Enterprises in Industry Development. iRegene is pioneering the future of regenerative medicine with its AI-powered, chemically induced cell therapy platform. By combining cutting-edge technology, a robust R&D ecosystem, and a globally experienced leadership team, iRegene is redefining allogeneic therapies to make them safer, more effective, and broadly accessible. This recognition highlights iRegene's continued leadership in innovation and its commitment to transforming patient care through next-generation regenerative therapies.
iRegene Therapeutics Honored as 2025 Forbes China Leading Enterprises in Industry Development
Aroop Zutshi, Global Managing Partner and Executive Board Director of Frost & Sullivan, and Junyi Guo, General Manager of Business Operations at Forbes China, jointly presented the 2025 Forbes China Leading Enterprises in Industry Development award. Dr. Jun Wei, Chairman of iRegene Therapeutics, was invited to attend the gala.
AI-Driven Chemical-Induced Cell Therapy: Reshaping the Future of Accessible Cell Therapy
Since its establishment in 2017, iRegene Therapeutics has remained committed to addressing unmet clinical needs through the development of next-generation cell therapies. With a focus on chemically induced, universal cell therapy products, iRegene aims to deliver transformative treatments for patients with currently incurable diseases.
iRegene Therapeutics has a proprietary, AI-based platform for screening chemical compounds to modify specific cellular functions. The platform leverages induced pluripotent stem cells (iPSCs) to enhance treatment potential. By combining compounds to form a chemically induced culture medium, the "AI+Chem" platform can efficiently and precisely reprogram or optimize a cell's fate and function, thereby enhancing the clinical capabilities of cell therapies.
With a focus on the chemical induction system, iRegene has developed a comprehensive research and development (R&D) ecosystem and an international patent system that spans the industry. This ecosystem combines the discovery of 'cell fate determinants', the screening of chemical inducers and the validation of cellular function. The system does not use viral vector construction or transgenic methods; the straightforward CMC procedure is cost-efficient. Furthermore, cell transformation and functional optimization are entirely driven by the cells' natural genetic makeup. Transformation is synchronous under chemically enhanced regulation, eliminating the risk of genetic modification. iRegene's pioneering platform has been proven through the positive outcomes of the Phase I clinical trial.
In addition, iRegene's executive team has an international perspective, with all members having successful overseas experience in their specialized fields. CEO Dr Wei Jun is a leading expert in regenerative medicine and the induced pluripotent stem cell (iPSC) technology, bringing strategic leadership to the company. Chief Medical Officer Dr Cai Meng has extensive experience taking innovative therapies from discovery through clinical development, while Chief Quality Officer Ren Xiang is a senior regulatory expert who provides solid support from IND approval to NDA clearance in China, the US, and other countries. Executive Vice President Emmanuel Montet, formerly Vice President of the Asia-Pacific region at Ipsen, now leads iRegene's global business development and international strategy.
To accelerate global clinical translation and commercialization, iRegene places great emphasis on the philosophy of 'cooperation and mutual benefit'. At the end of 2021, iRegene entered a long-term collaboration with Danaher Corporation to co-develop next-generation platforms for clinical application. Under this partnership, Danaher will play an active role in developing multi-directional platforms for future iRegene Therapeutics projects. This will involve supplying advanced detection instruments and technical resources relating to life sciences research, the development of effective compounds and screening, multi-omics cell mechanism research, and multi-substance screening. Danaher will help iRegene Therapeutics to enhance the efficiency of platform construction and its ability to deliver practical solutions. Danaher will also support iRegene Therapeutics in developing distinctive, innovative drug pipelines and establishing a research and production base. This strategic cooperation has recently been elevated to the iRegene - Danaher Joint Innovation Center, which is the world's first "Joint Innovation Center for Chemically Induced Therapies and Microphysiology Systems". The center will focus on integrating artificial intelligence (AI)-driven chemically induced cell therapy R&D with microphysiology systems technology. It is committed to accelerating the clinical translation and application of innovative therapies, and providing patients globally with more precise and effective treatment solutions for diseases. Danaher will fully support iRegene Therapeutics' future planning and development, aiming to jointly advance innovative development in China's life sciences research.
iRegene's breakthrough technology platform, strategic advantages and dedicated team have secured continuous support from several leading venture capital firms, with cumulative financing reaching nearly 400 million RMB (55.5 million USD). The company is advancing multiple programs through clinical development, targeting a win-win situation for its products and the capital markets alike, while providing patients around the world with next-generation chemically induced cell therapies that can genuinely reverse disease progression.
About iRegene Therapeutics
iRegene Therapeutics is a biotechnology company committed to becoming a global leader in universal chemical-induced cell therapy. As one of the first companies to harness AI and + chemical induction for the specific functional modification of cells, iRegene offers a safer, more scalable, and cost-effective alternative to traditional gene or cell therapies. Its pipeline targets diseases with high unmet need, including neurodegenerative disorders such as Parkinson's disease and blindness. Through pioneering science, strategic global partnerships, and a visionary leadership team, iRegene is reshaping the future of regenerative medicine - making advanced therapies accessible to patients worldwide.
In August 2023, the NMPA approved the commencement of Phase I clinical trials for iRegene's first product: 'Human Dopaminergic Precursor Cell, NouvNeu001'. This product was developed using the 'AI+ Chem' platform. This made it the world's first chemically induced pluripotent stem cell (iPSC)-derived therapy to enter clinical trials. In June 2024, it was approved by the U.S. FDA for overseas clinical trials. Even more groundbreakingly, in March 2024, iRegene's 'Chemical Induction Platform' became the first system ever to be granted exemption by the FDA. The company's second product, NouvNeu003, which is intended for the treatment of early-onset Parkinson's disease, received NMPA approval in December 2023 and entered Phase I clinical trials. Both NouvNeu001 and NouvNeu003 have now completed Phase I trials. The Phase I results demonstrate good safety, tolerability, and encouraging efficacy in improving motor and non-motor symptoms. The Phase II trial for NouvNeu001 began in April 2025. In parallel, iRegene's first-in-class ophthalmic therapy, was granted Orphan Drug Designation (ODD) by the U.S. FDA in March 2024.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
33 minutes ago
- Globe and Mail
Boeing shares fall 5% after Air India Dreamliner jet crashes, killing more than 200
Boeing Co.'s BA-N shares fell 5 per cent on Thursday after an Air India 787-8 Dreamliner jet crashed minutes after taking off, posing a major setback for the plane maker as its new CEO looks to rebuild trust following a series of safety and production challenges. All 242 people on board the London-bound plane were killed in the crash in the western city of Ahmedabad, authorities said, in the world's worst aviation disaster in a decade. It was not immediately clear what caused the crash. Boeing said in a statement it was aware of initial reports and was working to gather more information. The fatal crash tarnishes the Dreamliner jet's safety record and muddies CEO Kelly Orthberg efforts to ramp up production as the airplane maker scored a flurry of new orders and hit production targets in May, heading into the Paris air show. The widebody 787 planes, one of the most modern passenger aircraft in service, have never had a fatal crash until the Air India incident. They were grounded in 2013 due to battery issues, but no one was reported injured. Boeing, however, has faced years of scrutiny and delays over its narrowbody 737 MAX jets, which were grounded for years following two fatal crashes. Last year, the U.S. plane maker came under renewed scrutiny after a door plug blew off a 737 MAX 9 mid-flight, prompting a temporary FAA grounding and fresh concerns over quality control. Shares of Spirit AeroSystems Holdings Inc. SPR-N, a key supplier, and GE Aerospace GE-N, which makes engines for the jet, also fell about 3 per cent each. GE Aerospace said in a post on X that it had activated its emergency response team and would support the investigation, but did not specify if the Air India aircraft was equipped with its engines. The engine maker did not immediately respond to a Reuters request for comment. Boeing shares were trading at $196.75 after falling as much as 8 per cent before the opening bell. 'It's a knee-jerk reaction [to the incident] and there's revised fears of the problems that plagued Boeing aircraft and Boeing itself in recent years,' said Chris Beauchamp, analyst at IG Group.
Globe and Mail
37 minutes ago
- Globe and Mail
CVX, BP, SHEL: Global Energy Investments to Hit Record $3.3 Trillion in 2025
Global energy investments are forecast to hit a record $3.3 trillion this year, with two-thirds of that money going towards clean technologies, according to a new report by the International Energy Agency (IEA). Confident Investing Starts Here: The IEA says that investors appear to be shrugging off economic and geopolitical uncertainty and continuing to put money to work in the energy sector. That said, oil spending is projected to fall this year for the first time since 2020. The Paris-based IEA said in its annual investment report that the focus of investment dollars remains clean technologies, with $2.2 trillion going to renewable energy projects, nuclear power, grid upgrades, electrification, and low-emission fuels. 'Age of Electricity' The agency added that 2025 is the year when the world will officially enter what it calls the 'Age of Electricity,' underpinned by rapid uptake of electric vehicles. Meanwhile, investments in oil, natural gas, and coal are likely to reach $1.1 trillion in 2025. The overall $3.3 trillion investment this year marks a 2% increase from 2024 levels. The record spending is positive for both traditional oil and gas companies such as Chevron (CVX), British Petroleum (BP), and Shell (SHEL), as well as clean energy companies such as NextEra Energy (NEE) and battery maker Quantumscape (QS). China is expected to be the largest energy investor, accounting for more than a quarter (25%) of total spending. And the solar sector is forecast to be the biggest recipient of the investment dollars, with $450 billion funneled to the industry this year. Is CVX Stock a Buy? The stock of Chevron has a consensus Moderate Buy rating among 18 Wall Street analysts. That rating is based on 10 Buy, six Hold, and two Sell recommendations assigned in the past three months. The average CVX price target of $159.50 implies 11.27% upside from current levels. Disclaimer & Disclosure Report an Issue
CTV News
an hour ago
- CTV News
BC Ferries union upset Chinese company was hired to build new vessels
Following the selection of a Chinese state-run firm to build four new vessels, backlash has been strong and swift. News that BC Ferries has hired a Chinese company to build four new vessels for its aging fleet has generated choppy waters, including from the company's workers. 'We listened to the prime minister say, 'build, baby, build,' we listened to the prime minister say, 'buy B.C.' You know my members are going to the grocery store – I'm going to the grocery store – we're picking the fruits and vegetables that are local to Canada,' said Eric McNeely, with the BC Ferry and Marine Workers' Union. The value of the contract hasn't been released, but the union thinks the jobs should stay in B.C. to bolster shipbuilding in the province. 'A generational impact in shipbuilding,' said McNeely Wednesday, describing the potential impact of the four new major vessels. 'We're probably looking at a billion dollars of ship investment.' Amid a trade war with China that includes tariffs on Canadian seafood and tensions between the U.S. and China, the opposition B.C. Conservative Leader John Rustad is also upset. 'My big concern here is the instability, the friction that's building between United States and China,' said Rustad. Transportation Minister Mike Farnworth emphasized Wednesday that BC Ferries is not a Crown corporation, even if it gets significant funding from the province. He too says he's disappointed by the decision to hire a Chinese shipyard to do the work, but is heartened that the maintenance and repair contracts will stay in B.C. 'On something like this, you always want to see as much Canadian content as possible, as much British Columbian content as possible, so that's my main concern,' said Farnworth Wednesday. BC Ferries says no Canadian company bid on the project, adding Chinese shipbuilders now account for two thirds of global builds, and the winning bidder is responsible for Canadian ships, along with others around the world. 'This particular shipyard has really focused on the exact type of vessel that BC Ferries needs - specifically, large, high-quality roll-on. roll-off passenger ferries,' said Ed Hooper with BC Ferries. The new vessels are scheduled to be done between 2029 and 2031. B.C.'s main shipbuilder and the obvious local choice, Seaspan, says it's too busy with federal projects - navy and coast guard ships - to meet the project's timeline, but wants a piece of future contracts with three more builds already expected when these are done.
